The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBraveheart Inv Regulatory News (BRH)

Share Price Information for Braveheart Inv (BRH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.50
Bid: 6.00
Ask: 7.00
Change: 0.00 (0.00%)
Spread: 1.00 (16.667%)
Open: 6.50
High: 6.50
Low: 6.50
Prev. Close: 6.50
BRH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Further investment in Conjunct

20 Dec 2011 07:00

RNS Number : 2706U
Braveheart Investment Group plc
20 December 2011
 



20 December 2011

 

 

 

Braveheart Investment Group plc

 

Further investment in Conjunct Limited

 

 

Braveheart Investment Group (AIM: BRH) ('Braveheart' or the 'Group'), the AIM-listed specialist in growth capital investments for business angels, high net worth individuals and family offices, announces that it has led a third round of funding for its portfolio company Conjunct Limited. Investors in the c£340,000 round included the Group, Braveheart clients and Scottish Investment Bank's Scottish Co-investment Fund.

 

With the growth of the internet and an unprecedented demand for faster data transfer, fibre optic cabling is becoming mainstream, replacing traditional copper cables. To achieve faster connectivity within the fibre optic cable networks and support higher data rates, Conjunct has developed a highly innovative transceiver module, Fibre-Lyte. It is a novel packaging solution which can be applied to both datacoms and telecoms markets and has the potential to support data rates up to 300Gbps.

 

Conjunct, which is based in Livingston, central Scotland, has engaged with global organisations to integrate Fibre-Lyte into their product lines. The new money will be used to support Conjunct's production engineering activities for Fibre-Lyte manufacture and to complete development of a new Fibre-Lyte variant.

 

Geoffrey Thomson, Chief Executive of Braveheart, said: "Conjunct is now well placed to take advantage of the high demand for innovative optoelectronic solutions such as Fibre-Lyte and Conjunct is now in advanced discussions with the leading market players in optical systems."

 

Ken Allstaff, CEO of Conjunct, commented: "We are keen to move to the next stage of the Company's growth and are delighted to have again secured backing from Braveheart to allow us to offer Fibre-Lyte at costs and quantities which will enable continued market traction."

 

For further information please visit www.braveheartinvestmentgroup.co.uk and www.conjunct.co.uk or contact:

 

Braveheart Investment Group

Conjunct Limited

Geoffrey Thomson, Chief Executive

Ken Allstaff, Chief Executive

Tel: 01738 587555

Tel: 01506 465700

gthomson@braveheart-ventures.co.uk

ken.allstaff@conjunct.co.uk

 

 

Seymour Pierce Limited

Allerton Communications (for Braveheart)

Freddy Crossley (Nominated Adviser)

Peter Curtain

Paul Jewell / David Banks (Corporate broking)

Tel: 020 3137 2500

Tel: 020 7107 8000

peter.curtain@allertoncomms.co.uk

 

Notes to Editors

Braveheart Investment Group makes and manages investments in young, emerging British companies, specialising in building tax efficient portfolios for business angels, high net worth individuals and family offices. Braveheart was founded in 1997 by a small group of investors to encourage and syndicate investments in privately held companies that offered opportunities for significant growth. Fourteen years on, Braveheart is a public company with a demonstrable track record in technology investing, an established client base and various funds under management. The Group has offices in Perth, London, Yorkshire and Jersey with franchise operations in Dubai and Manchester.

 

Investments are made in unlisted companies where there is potential for significant growth through successful commercialisation of IP. Through close relationships with leading universities and innovation centres, Braveheart has access to a wide variety of emerging commercial opportunities at early stages. There are currently some 45 companies in Braveheart's diverse portfolio (includes all companies where the Group has a financial interest) and it has completed more than 90 deals.

 

Following the 2010 acquisition of Envestors Limited, the London based specialist corporate finance advisory business, Braveheart offers a unique and comprehensive suite of tax efficient products to high net worth investors.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCTLBFTMBMBBAB
Date   Source Headline
29th Apr 20242:07 pmRNSHolding(s) in Company
29th Apr 20241:42 pmRNSBlock admission six monthly return
10th Apr 20247:00 amRNSHolding(s) in Company
27th Mar 202412:03 pmRNSHolding(s) in Company
6th Mar 20247:00 amRNSAcquisition of further interest in Autins Group
4th Mar 202411:48 amRNSInvestment update – Paraytec Limited
4th Mar 20247:00 amRNSCompletion of sale of Phasefocus
9th Jan 202412:00 pmRNSHolding(s) in Company
22nd Dec 20231:30 pmRNSHolding(s) in Company
22nd Dec 20237:00 amRNSPortfolio update - Proposed sale of Phasefocus
15th Dec 202311:41 amRNSInvestment update - Paraytec Limited
15th Dec 202310:16 amRNSReplacement: Half-year Report
14th Dec 20237:00 amRNSHalf-year Report
29th Nov 20237:00 amRNSInvestment update - Paraytec Limited
14th Nov 20239:02 amRNSHolding(s) in Company
17th Oct 20237:00 amRNSInvestment update – Paraytec Limited
10th Oct 202311:15 amRNSHolding(s) in Company
8th Sep 20237:00 amRNSInvestment update – Kirkstall Limited
8th Sep 20237:00 amRNSBlock admission six monthly return
21st Aug 20237:00 amRNSFurther investment in Phasefocus Holdings Limited
28th Jul 20232:25 pmRNSInvestment update on Paraytec Limited
28th Jul 202311:54 amRNSResult of AGM
5th Jul 20237:00 amRNSPosting of annual report and notice of AGM
4th Jul 20237:00 amRNSHolding(s) in Company
3rd Jul 20237:00 amRNSFinal Results for the year ended 31 March 2023
31st May 20237:00 amRNSInvestment update – Phasefocus Holdings Limited
3rd May 20237:00 amRNSUpdate on investments
24th Apr 202310:49 amRNSHolding(s) in Company
27th Mar 20237:00 amRNSGrant of options
13th Mar 20239:34 amRNSHolding(s) in Company
9th Mar 20237:00 amRNSBlock admission six monthly return
10th Feb 20231:26 pmRNSHolding(s) in Company
30th Jan 20234:37 pmRNSHolding(s) in Company
16th Jan 20237:00 amRNSDirector/PDMR Shareholding
10th Jan 20237:00 amRNSOperational update
22nd Dec 20229:14 amRNSHolding(s) in Company
19th Dec 20229:25 amRNSDirector/PDMR Shareholding
19th Dec 20229:11 amRNSAcquisition of interest in Image Scan Holdings plc
13th Dec 20224:37 pmRNSHolding(s) in Company
15th Nov 20223:09 pmRNSHolding(s) in Company
7th Nov 20227:00 amRNSDirector/PDMR Shareholding
28th Oct 20227:00 amRNSHalf-year Report
21st Oct 202210:33 amRNSHolding(s) in Company
20th Oct 20221:59 pmRNSAcquisition of further interest in Autins
5th Oct 20223:15 pmRNSHolding(s) in Company
5th Oct 202212:28 pmRNSAcquisition of further interest in Aukett Swanke
30th Sep 20225:00 pmRNSTotal Voting Rights
20th Sep 20227:00 amRNSPlacing and subscription to raise £750,000
9th Sep 20227:00 amRNSBlock admission six monthly return
6th Sep 20227:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.